SCHEMBL368186

SCHEMBL368186

c1ncn2c1CCCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933129 0.93
Phosphoric Acid SCHEMBL23064073 0.89 PDPK1 (0.35)
SCHEMBL19045076 0.72 HRH3 (0.35)
SCHEMBL16373622 0.71 NAMPT (0.31)
SCHEMBL23277737 0.69
SCHEMBL20674574 0.69 CYP19A1 (0.36)
SCHEMBL6068456 0.67
SCHEMBL7547068 0.67
SCHEMBL18366226 0.66 HSD17B10 (0.35)
SCHEMBL9941956 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317753-A9 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2024-09-26 US claimed
US-20230286973-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2023-09-14 US claimed
EP-4204417-A1 PROTEIN SECRETION INHIBITORS Kezar Life Sciences (US) 2023-07-05 EP claimed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US claimed
CN-116194455-A Protein secretion inhibitor 科智生命科学公司 2023-05-30 CN claimed
WO-2022047347-A1 PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2022-03-03 WO claimed
US-20090118512-A1 Process for Preparing 6,7-Dihydro-5H-Imidazo[1,5-A]Pyridin-8-One SPEEDEL EXPERIMENTA AG (CH) 2009-05-07 US claimed
EP-2001850-A1 PROCESS FOR PREPARING 6,7-DIHYDRO-5H-IMIDAZOÝ1,5-A¨PYRIDIN-8-ONE Speedel Experimenta AG (CH) 2008-12-17 EP claimed
WO-2007113235-A1 PROCESS FOR PREPARING 6,7-DIHYDRO-5H-IMIDAZO[1,5-A]PYRIDIN-8-ONE SPEEDEL EXPERIMENTA AG (CH) 2007-10-11 WO claimed
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US claimed
EP-0659082-B1 USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE WARNER LAMBERT CO (US) 2002-02-06 EP claimed
US-5547961-A USING TETRAHYDROIMIDAZOPYRIDINE YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1996-08-20 US claimed
US-5466696-A Mixtures for treatment of alzheimer's disease WARNER LAMBERT COMPANY (US) 1995-11-14 US claimed
EP-0114573-B1 IMIDAZO(1,5-A)PYRIDINE DERIVATIVES CIBA-GEIGY AG (CH) 1988-04-20 EP claimed
EP-0070389-B1 2-(2-FLUORO-4-HALO-5-SUBSTITUTED PHENYL) HYDANTOINS, AND THEIR PRODUCTION AND USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-10-02 EP claimed
US-4307101-A ANTIHISTAMINES AND ANTISECRETORY AGENTS OF THE THIOUREA OR UREA DERIVATIVES 5,6,7,8-TETRAHYDROIMIDAZO(1,5A)PYRIDINE SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1981-12-22 US claimed
JP-2091074-A None JP disclosed
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
US-3950353-A HISTAMINE INHIBITORS SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1976-04-13 US disclosed
US-3950333-A HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1976-04-13 US disclosed